Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/56010| Title: | Pharmacokinetics of unboosted atazanavir in treatment-experienced HIV-infected children, adolescents and young adults |
| Authors: | Tim R. Cressey Rohan Hazra Andrew Wiznia Marc Foca Patrick Jean-Philippe Bobbie Graham Jennifer R. King Paula Britto Vincent J. Carey Edward P. Acosta Ram Yogev |
| Authors: | Tim R. Cressey Rohan Hazra Andrew Wiznia Marc Foca Patrick Jean-Philippe Bobbie Graham Jennifer R. King Paula Britto Vincent J. Carey Edward P. Acosta Ram Yogev |
| Keywords: | Medicine |
| Issue Date: | 28-Nov-2016 |
| Abstract: | © 2016 Wolters Kluwer Health, Inc. All rights reserved. HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population. |
| URI: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84984700603&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/56010 |
| ISSN: | 15320987 08913668 |
| Appears in Collections: | CMUL: Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.